Research article · 12 Jun 2025
Conference abstractPublished 2018
Tumor microenvironment-targeted bacteriochlorophylls as theranostic agents for triple negative breast cancer
Weizmann Institute of Science, Israel Memorial Sloan Kettering Cancer Center, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background & Purpose: Cytotoxic drugs that target specific receptors on cancer cells and supporting vasculature often fail to convey significant therapeutic benefit, despite their extensive tumor uptake and high toxicity in cell cultures. A recent example is provided by Cilengitide®, a cyclic Arg-Gly-Asp (cRGD) that accumulates in tumors but fails to delay cancer progression. In this study, we rationalized the current failure of cRGD based clinical trials by assessing the tumor heterogeneity, showing that significant populations of cancer and endothelial cells do not accumulate the cRGD agents. Method: We further tested the hypothesis that bystander cell death propagation initiated by agents coupled to cRGD molecules can effectively eradicate the entire tumor even if taken by the limited cell populations. The new approach was applied to mice grafted with metastatic 4T1 tumors in their mammary pad. This model is considered good representative for triple Negative Breast Cancer (TNBC), a heterogeneous disease with distinct molecular subtypes that differentially respond to chemotherapy and targeted agents with high rate of treatment failure and mortality. Result: Using STL-6014, a cRGD tagged with a fluorescing and photoactive bacteriochlorophyll derivative (Bchl-D), we showed that STL-6014 can specifically and non-invasively target orthotopic TNBC tumors as well as lung metastatic tumor lesions trough integrin receptors expressed on different cell populations. The apparent high tumor uptake reflects the integrin expression by these cells. High cRGD uptake confers death of cancer and stroma cells while cells lacking integrin expression remains alive and drive tumor proliferation. This therapeutic obstacle is solved by self-promoting death signal initiated by photo-activation of the Bchl-D tags in the β3 expressing cells. Rapid propagation of cell apoptosis/necrosis via bystander effect results 62% primary tumor ablation in mice bearing 4T1. Conclusion: The study provides rationale and new means for paradigm shift in cell-targeted therapies, understanding and overcoming failures of therapies that target specific cell populations in the tumor microenvironment.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Pharmaceutics & Drug Delivery Research.
Research article · 20 Feb 2025
Sustained Drug Delivery in Pharmaceutical Dosage Forms for Novel Approaches of Formulation Design
Research article · 23 Jan 2025
Cutting Out Counterfeits: How Blockchain Can Revolutionize Drug Traceability?
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmaceutics & Drug Delivery Research
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Lilach Agemy”
- BylineArticles whose byline prints “Rachel Hamri”
- BylineArticles whose byline prints “Tamar Yechezkel”
- BylineArticles whose byline prints “Ronny Uzana”
- BylineArticles whose byline prints “Jonathan A Coleman”
- BylineArticles whose byline prints “Susan F Slovin”
- BylineArticles whose byline prints “Yoram Salomon”
- BylineArticles whose byline prints “Avigdor Scherz”
